Acquisition Completed
Fresenius acquisition of mAbxience
€1.7bn equity value
Announced Oct 2026 (approx.)
Advisers
mAbxience
Target
Not disclosed
- Target
- mAbxience
- Acquirer
- Fresenius
- Target based in
- Spain
- Buyer based in
- Germany
- Completed
- 1 Oct 2026
- Stake
- 45%
- Sector
- Biotech
- Tags
- Biotech, Pharma
Similar deals
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
- Sanofi acquisition of Dynavax Technologies Dec 2025 · US$2.2bn · Biotech
- Eli Lilly and Company acquisition of Orna Therapeutics Feb 2026 · US$2.4bn · Biotech
- Servier acquisition of Day One Biopharmaceuticals Mar 2026 · US$2.5bn · Biotech
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
